[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-353421-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-353421-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","targeted-immunotherapies-for-anaplastic-lymphoma-kinase-positive-pediatric-tumors-current-advances-and-future-perspectives","Targeted immunotherapies for anaplastic lymphoma kinase-positive pediatric tumors - current advances and future perspectives","","Targeted immunotherapies for anaplastic lymphoma kinase (ALK)-positive pediatric tumors are reviewed with emphasis on current advances and future perspectives. Pediatric cancer remains a leading cause of childhood and adolescent mortality, while standard modalities often cause severe long-term toxicities and many patients face relapse or refractory disease. ALK acts as a key oncogenic driver in multiple pediatric malignancies, and although ALK tyrosine kinase inhibitors can benefit patients, resistance motivates alternative strategies. The review highlights ALK-directed immunotherapies including vaccines, ALK CAR-T and other cellular approaches, and ALK-targeting antibodies, focusing on rationale and preclinical efficacy with implications for safer, more durable disease control.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/targeted-immunotherapies-for-anaplastic-lymphoma-kinase-positive-pediatric-tumors-current-advances-and-future-perspectives/353421/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/targeted-immunotherapies-for-anaplastic-lymphoma-kinase-positive-pediatric-tumors-current-advances-and-future-perspectives/353421.png","ImageObject",300,407,{"name":42,"@type":43},"CatatanPagi","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why are targeted immunotherapies needed for ALK-positive pediatric tumors?","Question",{"text":63,"@type":64},"Standard pediatric therapies can lead to severe long-term toxicities, and many patients still experience resistance, relapse, or refractory disease. ALK-directed immunotherapies are presented as biologically rational options that may help address these challenges, including resistance to ALK tyrosine kinase inhibitors.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What role does ALK play in pediatric malignancies?",{"text":68,"@type":64},"ALK is described as a critical driver of tumorigenesis in several pediatric cancers, including ALCL, neuroblastoma, and inflammatory myofibroblastic tumor. ALK is also characterized as an oncoantigen supported by ALK-specific humoral and T-cell responses in ALK-positive ALCL patients.",{"name":70,"@type":61,"acceptedAnswer":71},"Which ALK-directed immunotherapy approaches are discussed in the review?",{"text":72,"@type":64},"The review covers ALK-specific immunotherapies including ALK vaccines, ALK CAR-T and other cellular therapies, and ALK-targeting antibodies. It focuses particularly on pediatric ALK-positive tumors.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},353421,1790507164,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":108,"slug":109},7,40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},8,"Research & Report",30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":107,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145},962090894170,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","TYPE Review  \nPUBLISHED 14 August 2026  \nDOI 10.3389/fimmu.2026.1912199  \nOPEN ACCESS  \nEDITED BY  \nFederica Riccardo, University of Turin, Italy  \nREVIEWED BY  \nAmitabh Singh,  \nVardhman Mahavir Medical College & Safdarjung Hospital, India  \nLianna Jean Marks,  \nStanford University, United States Mahdi Mehmandoost,  \nShahid Beheshti University of Medical Sciences, Iran  \n*CORRESPONDENCE  \nClaudia Voena  \n claudia.voena@unito. it Roberto Chiarle  \n roberto. chiarle@unito. it  \n†These authors have contributed equally to this work  \nRECEIVED 17 June 2026  \nREVISED 21 July 2026  \nACCEPTED 24 July 2026  \nPUBLISHED 14 August 2026  \nCITATION  \nMaccagno M, Tagliero R, Chiarle R and  \nVoena C (2026) Targeted immunotherapies for anaplastic lymphoma kinase-positive pediatric tumors: current advancesand future perspectives.  \nFront. Immunol. 17:1912199 .  \ndoi: 10.3389/fimmu.2026.1912199  \nCOPYRIGHT  \n© 2026 Maccagno, Tagliero, Chiarle and Voena. This is an open-access article distributed under the terms of the  \nCreative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nTargeted immunotherapies for anaplastic lymphoma kinasepositive pediatric tumors: current advances and future perspectives  \nMonica Maccagno 1†, Roberta Tagliero 1†, Roberto Chiarle 1,2,3* and Claudia Voena 1*  \n1 Department of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center, University of Torino, Torino, Italy, 2 Department of Hematopathology, IEO European Institute of Oncology IRCCS, Milan, Italy, 3 Department of Pathology, Children’s Hospital and Harvard Medical School, Boston, MA, United States  \nEditorial on the research topic: Next-Generation Treatment for Pediatric Cancer: Advancing Immunotherapy through Combinations. Cancer remains one of the leading causes of disease-related mortality among children and adolescents. Despite advances in treatments, outcomes for many pediatric tumors remain limited, particularly in patients with high-risk, relapsed, or refractory disease. Standard therapies, including surgery, chemotherapy, radiotherapy, and stem cell transplantation, are frequently associated with severe long-term toxicities and secondary malignancies. Resistance and relapse remain major clinical challenges. Recent progress in cancer immunotherapy has revolutionized adult oncology, and remarkable clinical advances have been observed in several pediatric cancers. However, comparable benefits in most solid tumors remain limited. Among molecular targets, anaplastic lymphoma kinase (ALK) has emerged as a critical driver of tumorigenesis in several pediatric malignancies, including anaplastic large cell lymphoma (ALCL), neuroblastoma and inflammatory myofibroblastic tumor. While ALK tyrosine kinase inhibitors have demonstrated clinical benefit, the emergence of resistance highlights the need for alternative or complementary strategies. ALK can act as an oncoantigen, as shown by spontaneous ALK-specific humoral and T-cell responses in patients with ALKpositive ALCL, and ALK-directed immunotherapies have been developed and have shown efficacy in preclinical models of ALK-positive tumors, including ALCLand neuroblastoma. Therefore, ALK-directed immunotherapies represent biologically rational and promising approaches that may, if proven safe and effective in clinical trials, address resistance and improve long-term disease control. In this review, we will discuss ALK-specific immunotherapies, including ALK vaccines, ALK CAR-T and other cellular therapies, as well as ALK-targeting antibodies with a particular focus on pediatric ALK-positive tumors.  \nKEYWORDS  \nALK-positive tumors, anaplastic lymphoma kinase (ALK), antibody-drug co","cbCain5yJpMbih0F","https://ap.wps.com/l/cbCain5yJpMbih0F","pdf",2311397,15,"English","# Introduction\n## Editorial on the research topic: Next-Generation Treatment for Pediatric Cancer\n## Rationale for ALK as a molecular target\n## Scope of the review and key immunotherapy modalities\n# Keywords","[{\"question\":\"Why are targeted immunotherapies needed for ALK-positive pediatric tumors?\",\"answer\":\"Standard pediatric therapies can lead to severe long-term toxicities, and many patients still experience resistance, relapse, or refractory disease. ALK-directed immunotherapies are presented as biologically rational options that may help address these challenges, including resistance to ALK tyrosine kinase inhibitors.\"},{\"question\":\"What role does ALK play in pediatric malignancies?\",\"answer\":\"ALK is described as a critical driver of tumorigenesis in several pediatric cancers, including ALCL, neuroblastoma, and inflammatory myofibroblastic tumor. ALK is also characterized as an oncoantigen supported by ALK-specific humoral and T-cell responses in ALK-positive ALCL patients.\"},{\"question\":\"Which ALK-directed immunotherapy approaches are discussed in the review?\",\"answer\":\"The review covers ALK-specific immunotherapies including ALK vaccines, ALK CAR-T and other cellular therapies, and ALK-targeting antibodies. It focuses particularly on pediatric ALK-positive tumors.\"}]","Targeted immunotherapies for anaplastic lymphoma kinase-positive pediatric tumors - current advances and future perspectives | PDF",1790105266,38]